FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:2183-2186 November 22, 2007 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Dimopoulos, M. Related Article by Weber, D. M. PubMed Citation

Perhaps the darkest memory in modern pharmaceutical history is that of the devastating effects of thalidomide exposure on fetal development. More than four decades later, thalidomide reemerged from the ashes as the prototype for a new proprietary class of drugs with broad pharmacologic effects and promising antineoplastic activity, referred to collectively as immunomodulatory drugs.

Thalidomide was first marketed in Europe in the late 1950s as a hypnotic and antiemetic for the treatment of morning sickness during pregnancy. Between 1956 and 1962, approximately 10,000 children were born with severe physical deformities, or phocomelia, as a result of the drug's unrecognized teratogenic . . . [Full Text of this Article]

Source Information

From the H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.